Matt Phipps
Stock Analyst at William Blair
(0.63)
# 4,061
Out of 5,055 analysts
23
Total ratings
37.5%
Success rate
-15.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matt Phipps
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KZR Kezar Life Sciences | Downgrades: Market Perform | n/a | $6.18 | - | 3 | Oct 17, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | n/a | $1.91 | - | 1 | Oct 16, 2025 | |
| INSM Insmed | Initiates: Outperform | n/a | $193.22 | - | 1 | Aug 20, 2025 | |
| INKT MiNK Therapeutics | Downgrades: Market Perform | n/a | $12.75 | - | 2 | Jul 14, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | n/a | $1.68 | - | 2 | Jul 7, 2025 | |
| CNTX Context Therapeutics | Initiates: Outperform | n/a | $1.16 | - | 1 | Apr 21, 2025 | |
| XNCR Xencor | Initiates: Outperform | n/a | $14.93 | - | 1 | Apr 21, 2025 | |
| GMAB Genmab | Upgrades: Outperform | n/a | $30.26 | - | 2 | Mar 11, 2025 | |
| KROS Keros Therapeutics | Downgrades: Market Perform | n/a | $17.26 | - | 1 | Dec 12, 2024 | |
| UPB Upstream Bio | Initiates: Outperform | n/a | $24.53 | - | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.10 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.55 | - | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $46.65 | - | 1 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $29.28 | - | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.07 | - | 1 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $167.55 | - | 2 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $96.01 | - | 1 | Apr 8, 2021 |
Kezar Life Sciences
Oct 17, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $6.18
Upside: -
Climb Bio
Oct 16, 2025
Initiates: Outperform
Price Target: n/a
Current: $1.91
Upside: -
Insmed
Aug 20, 2025
Initiates: Outperform
Price Target: n/a
Current: $193.22
Upside: -
MiNK Therapeutics
Jul 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $12.75
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $1.68
Upside: -
Context Therapeutics
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $1.16
Upside: -
Xencor
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $14.93
Upside: -
Genmab
Mar 11, 2025
Upgrades: Outperform
Price Target: n/a
Current: $30.26
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $17.26
Upside: -
Upstream Bio
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $24.53
Upside: -
Sep 30, 2024
Initiates: Outperform
Price Target: n/a
Current: $7.10
Upside: -
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $8.55
Upside: -
Oct 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $46.65
Upside: -
Nov 14, 2022
Initiates: Outperform
Price Target: n/a
Current: $29.28
Upside: -
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $9.07
Upside: -
Jun 8, 2021
Upgrades: Outperform
Price Target: n/a
Current: $167.55
Upside: -
Apr 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $96.01
Upside: -